Conference item
Feno and blood eosinophils as biomarkers in predicting asthma exacerbations
- Abstract:
- With advances in new therapies that target airway inflammation, there is an urgent need for accurate and easy-to-use biomarkers to predict asthma exacerbations and likely patient responses to treatment. Blood and sputum eosinophilia are used to predict the response of patients with asthma to steroid therapy. Similarly, fractional exhaled nitric oxide (FeNO) concentrations has been shown to predict response to antiinflammatory therapy. Efforts have been made to correlate FeNO and blood eosinophil counts as composite biomarkers but so far results have been inconsistent.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 605.4KB, Terms of use)
-
- Publisher copy:
- 10.1136/thoraxjnl-2017-210983.340
Authors
- Publisher:
- BMJ Publishing Group
- Host title:
- British Thoracic Society Winter Meeting 2017
- Journal:
- British Thoracic Society Winter Meeting 2017 More from this journal
- Publication date:
- 2017-11-15
- DOI:
- Pubs id:
-
pubs:855780
- UUID:
-
uuid:5899980a-dfdc-4c43-9ce2-fd3c8dcc7f8a
- Local pid:
-
pubs:855780
- Source identifiers:
-
855780
- Deposit date:
-
2018-08-30
- ARK identifier:
Terms of use
- Copyright holder:
- BMJ Publishing Group
- Copyright date:
- 2017
- Notes:
- © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is the accepted manuscript version of the article. The final version is available online from BMJ Publishing Group at: http://dx.doi.org/10.1136/thoraxjnl-2017-210983.340
If you are the owner of this record, you can report an update to it here: Report update to this record